早期BCR-ABL1动力学可预测慢性髓性白血病无治疗缓解的达成
该研究纳入115例尝试无治疗缓解(TFR)的慢性期CML患者,评估包括BCR-ABL1下降半衰期在内的多变量对持续TFR的影响。持续TFR概率为55%,BCR-ABL1半衰期是最强独立预测因素:<9.35天者持续TFR率80%,>21.85天者仅4%(P<.001)。e14a2转录本类型和TKI暴露时长亦为独立预测因素,而3个月BCR-ABL1值非独立预测因素。
要点
- BCR-ABL1半衰期<9.35天者持续TFR率80%,>21.85天者仅4%。
- e14a2转录本类型和TKI暴露时长是持续TFR的独立预测因素。
- 3个月BCR-ABL1值不是持续TFR的独立预测因素。
核心结论
- 起始TKI治疗后BCR-ABL1初始下降动力学对长期TFR结局具有关键重要性。
研究设计与样本
- 研究纳入115例尝试TFR且随访≥12个月的慢性期CML患者,评估多变量对持续TFR的影响。
主要发现
- 持续TFR(停TKI后维持主要分子学缓解12个月)的概率为55%。
- BCR-ABL1半衰期<9.35天(第一四分位)者持续TFR率为80%,>21.85天(第四四分位)者仅4%(P<.001)。
- e14a2 BCR-ABL1转录本类型和尝试TFR前TKI暴露时长也是持续TFR的独立预测因素。
- TKI治疗3个月时BCR-ABL1值不是持续TFR的独立预测因素。
- 起始TKI后BCR-ABL1下降更快与更可能获得TFR资格相关。
关键数值与推荐
- 持续TFR定义为停用TKI后维持主要分子学缓解12个月。
- BCR-ABL1半衰期<9.35天者持续TFR率80%,>21.85天者4%(P<.001)。
临床怎么用
- 可通过计算TKI治疗后BCR-ABL1半衰期早期识别持续TFR概率高的患者。
- BCR-ABL1半衰期较长者持续TFR概率低,需谨慎评估TFR尝试。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
With treatment-free remission (TFR) rapidly becoming the ultimate goal of therapy in chronic myeloid leukemia (CML), there is a need to develop strategies to maximize sustained TFR by improving our understanding of its key determinants. Chronic-phase CML patients attempting TFR were evaluated to identify the impact of multiple variables on the probability of sustained TFR. Early molecular response dynamics were included as a predictive variable, assessed by calculating the patient-specific halving time of BCR-ABL1 after commencing tyrosine kinase inhibitor (TKI) therapy. Overall, 115 patients attempted TFR and had ≥12 months of follow-up. The probability of sustained TFR, defined as remaining in major molecular response off TKI therapy for 12 months, was 55%. The time taken for the BCR-ABL1 value to halve was the strongest independent predictor of sustained TFR: 80% in patients with a halving time of <9.35 days (first quartile) compared with only 4% if the halving time was >21.85 days (last quartile) (P < .001). The e14a2 BCR-ABL1 transcript type and duration of TKI exposure before attempting TFR were also independent predictors of sustained TFR. However, the BCR-ABL1 value measured at 3 months of TKI was not an independent predictor of sustained TFR. A more rapid initial BCR-ABL1 decline after commencing TKI also correlated with an increased likelihood of achieving TFR eligibility. The association between sustained TFR and the time taken for BCR-ABL1 to halve after commencing TKI was validated using an independent dataset. These data support the critical importance of the initial kinetics of BCR-ABL1 decline for long-term outcomes.
引用
- Shanmuganathan N, Pagani IS, Ross DM, et al. Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia. Blood. 2021. PMID: 32871588. doi:10.1182/blood.2020005514
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。